Cargando…

Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients

Genetic screening of somatic mutations in circulating free DNA (cfDNA) opens up new opportunities for personalized medicine. In this study, we aim to illustrate the implementation of NGS-based liquid biopsy in clinical practice for the detection of somatic alterations in selected genes. Our work is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zulato, Elisabetta, Tosello, Valeria, Nardo, Giorgia, Bonanno, Laura, Del Bianco, Paola, Indraccolo, Stefano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394370/ https://www.ncbi.nlm.nih.gov/pubmed/34441402 http://dx.doi.org/10.3390/diagnostics11081468

Ejemplares similares

EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience
por: Dal Maso, Alessandro, et al.
Publicado: (2022)

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Zulato, Elisabetta, et al.
Publicado: (2022)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
por: Bonanno, Laura, et al.
Publicado: (2022)

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome
por: Pavan, Alberto, et al.
Publicado: (2021)

In situ Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology Approach
por: Piga, Ilaria, et al.
Publicado: (2020)

Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients
por: Boldrin, Elisa, et al.
Publicado: (2019)

Targeted Next-Generation Sequencing of Liquid Biopsy Samples from Patients with NSCLC
por: Mellert, Hestia, et al.
Publicado: (2021)

Liquid Biopsies in Cancer Diagnosis, Monitoring and Prognosis
por: Ulivi, Paola, et al.
Publicado: (2022)

LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective
por: Ciccarese, Francesco, et al.
Publicado: (2019)

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer
por: Zulato, Elisabetta, et al.
Publicado: (2020)

Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth
por: Zulato, Elisabetta, et al.
Publicado: (2018)

A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients
por: Cortiula, Francesco, et al.
Publicado: (2020)

LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
por: Bonanno, Laura, et al.
Publicado: (2019)

Metabolic classification of non-small cell lung cancer patient-derived xenografts by a digital pathology approach: A pilot study
por: Ferrarini, Federica, et al.
Publicado: (2023)

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment
por: Marchetti, Antonio, et al.
Publicado: (2014)

Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications
por: Bertoli, Elisa, et al.
Publicado: (2023)

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers
por: Pasini, Luigi, et al.
Publicado: (2019)

Next-generation sequencing in liquid biopsy: cancer screening and early detection
por: Chen, Ming, et al.
Publicado: (2019)

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control
por: Wu, Ting-Miao, et al.
Publicado: (2020)

Cancer stem cells from epithelial ovarian cancer patients privilege oxidative phosphorylation, and resist glucose deprivation
por: Pastò, Anna, et al.
Publicado: (2014)

Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation
por: Kwak, Jay Jiyong, et al.
Publicado: (2023)

Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients
por: Papadopoulou, Eirini, et al.
Publicado: (2019)

Liquid biopsy in NSCLC: a new challenge in radiation therapy
por: Perillo, Annarita, et al.
Publicado: (2021)

Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment
por: Bianchi, Fabrizio
Publicado: (2015)

Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis
por: Pang, Bairen, et al.
Publicado: (2020)

‘Longing’ for the Next Generation of Liquid Biopsy: The Diagnostic Potential of Long Cell-Free DNA in Oncology and Prenatal Testing
por: Yu, Stephanie C. Y., et al.
Publicado: (2023)

Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy
por: Del Re, Marzia, et al.
Publicado: (2019)

New methodology of TMB assessment from tissue and liquid biopsy in NSCLC
por: Křížová, Ľudmila, et al.
Publicado: (2022)

Metformin: a modulator of bevacizumab activity in cancer? A case report
por: Indraccolo, Stefano, et al.
Publicado: (2015)

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
por: Nelson, Valerie, et al.
Publicado: (2013)

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
por: Iacovino, Marialucia, et al.
Publicado: (2020)

Study of Liquid-Based Cytology Using Next-Generation Sequencing as a Liquid Biopsy Application in Patients with Advanced Oncological Disease
por: Peña, Karla Beatríz, et al.
Publicado: (2023)

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
por: Hirsh, Vera
Publicado: (2015)

Tumor molecular profiling of NSCLC patients using next generation sequencing
por: Tsoulos, Nikolaos, et al.
Publicado: (2017)

The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation
por: Alexandrou, George, et al.
Publicado: (2023)

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
por: Ferreira, Daniela, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero, Estela, et al.
Publicado: (2020)

Circulating noncoding RNAs: promising biomarkers in liquid biopsy for the diagnosis, prognosis, and therapy of NSCLC
por: Li, Yilin, et al.
Publicado: (2023)

Liquid biopsy: from discovery to clinical implementation
por: Alix‐Panabières, Catherine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bm38ggmibo0o95vhqgc5tjll3q